Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and ...
This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’ s PFE hemophilia ...
EUROPE NEWS DUBLIN—The Irish government is rolling in clover like never before. The country currently has so much money it pumps cash into not one but two sovereign-wealth funds. It is so flush that ...
Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union ...
Delhi: Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab) ...
"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZIâ„¢ (marstacimab) for the ...
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors: New York Thursday, November 21, 2024, 0 ...
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The ...
Pfizer (PFE) announced that the European Commission, or EC, has granted marketing authorization for Hympavzi for the routine prophylaxis of ...
Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the ...
Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...